$3M Gene Therapy—With a Catch - Summary - MDSpire

$3M Gene Therapy—With a Catch

Medicaid is testing a pay-for-performance deal that makes drugmakers refund millions if new sickle cell gene therapies fail.

  • By

  • Phil Galewitz

  • January 21, 2026

  • 8 min

Share

Objective:

To discuss the implications of a new gene therapy payment model for sickle cell disease treatment under Medicaid and its potential effects on the healthcare system.

Key Findings:
  • Gene therapies for sickle cell disease can potentially cure the condition but come with high costs of $2.2 million to $3.1 million per patient, raising concerns about affordability.
  • The new payment model aims to provide discounts and rebates if treatments do not work, differing from traditional Medicaid payment practices and potentially influencing future therapies.
  • The program is expected to increase access to gene therapies for more patients under Medicaid, but ongoing evaluation of patient outcomes will be crucial.
Interpretation:

The new payment model represents a significant shift in how expensive therapies are funded, potentially improving patient access while managing costs for Medicaid.

Limitations:
  • The clinical trials for the gene therapies involved fewer than 100 patients and followed them for only two years, raising concerns about long-term efficacy and the generalizability of results.
  • Details of the financial agreements between CMS and drug manufacturers remain confidential, complicating transparency.
Conclusion:

The gene therapy payment model could serve as a precedent for future high-cost treatments, but its success will depend on patient outcomes, ongoing evaluation, and broader access to therapies.

Original Source(s)

$3M Gene Therapy—With a Catch

  • by Phil Galewitz

  • January 21, 2026

Related Content

IPS Could Minimize GI Effects in Treating Iron Deficiency

Review summarizes pharmacokinetic and clinical data on iron protein succinylate across patients with iron deficiency and iron deficiency anemia.

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

ACS Collaborative May Improve Compliance in Lung Nodal Assessment

Community programs showed the largest gains in compliance with a surgical staging standard following participation in the Lung NODES collaborative.